In this study, we investigated whether elimination of CD4+ CD25+ Tregs using anti-CD25 mAbs (PC61) was capable of enhancing CCL21-mediated antitumor immunity in a mouse HCC model. Here, CD4 is linked to hepatocellular carcinoma.